New Combination for Asthma Shows Encouraging Results in Delivering Efficacy and Fast Onset of Action

CAMBRIDGE, England, September 19, 2010 – Data presented at the European Respiratory Society (ERS) congress
demonstrate that a new fixed-dose combination therapy of fluticasone
propionate (FP), an inhaled corticosteroid, and formoterol fumarate (FORM), a
long-acting beta2-agonist, is as effective in treating asthma as one of the
current market leaders in Europe, fluticasone propionate/salmeterol xinafoate
(FP/SAL), but has a more [...]

AQT90 FLEX Opens Up for a New and Better Way of Measuring Troponin T at the Point of Care

COPENHAGEN, September 20, 2010 – Radiometer has added the cardiac marker Troponin T* (TnT) to its AQT90
FLEX immunoassay analyzer for the use at the point of care. According to
Radiometer President Peter Kurstein, the new marker enables healthcare
professionals to improve processes in emergency rooms and labs, ultimately
helping hospitals improve patient care and reduce costs.

[...]

24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus

STOCKHOLM, September 20, 2010 – Bristol-Myers Squibb Company (NYSE: BMY)(www.bms.com) and
AstraZeneca (NYSE: AZN)(www.astrazeneca-us.com)
today announced results from a randomized, double blind Phase 3 clinical
study, which demonstrated that the addition of the investigational drug
dapagliflozin to existing glimepiride (sulphonylurea) therapy produced
significant reductions in glycosylated hemoglobin levels (HbA1c) in adult
patients with type 2 diabetes compared to glimepiride [...]

Sanofi-aventis: Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients With Type 2 Diabetes

Phase III Study Results Also Demonstrated the Therapy had Acceptable Safety Profile

PARIS, September 20, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today
the first Phase III results of the GetGoal clinical trial program assessing
the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist,
as monotherapy in patients with type 2 diabetes. These results [...]

Three Million Give ‘Thumbs Up’ to Saving Children’s Lives

Claire Danes to unveil unique visual petition in Grand Central Terminal on Monday 20th September, 1300 hrs

NEW YORK, September 20, 2010 – Emmy award-winning actress Claire Danes will join millions of people
who've added their thumbprints to an innovative and unique global petition at
Grand Central Terminal, lead by global humanitarian organisation Save the
Children.
[...]

CareFusion Launches Next-Generation Clinical Diagnostics Software for Jaeger(TM) and SensorMedics(R) Product Lines

HOCHBERG, Germany, September 20, 2010 – CareFusion (NYSE: CFN), a leading, global medical device company, today
announced the commercial release of SentrySuite(TM), the next-generation
clinical diagnostics software for the Jaeger(TM) and SensorMedics(R)
Pulmonary Diagnostics and CardioPulmonary Diagnostics instruments.

SentrySuite is an innovative set of software applications to assist with
clinically intelligent diagnostics to improve the [...]

Boston Scientific Receives Exclusive Expanded Indication for its CRT-Ds

FDA Approval is Based on Results From the Company's Landmark MADIT-CRT Trial

NATICK, Massachusetts, September 20, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced that
the U.S. Food and Drug Administration (FDA) has approved an expanded
indication for its cardiac resynchronization therapy defibrillators (CRT-Ds),
including the COGNIS(R) CRT-D. The exclusive expanded indication is effective
immediately and makes Boston [...]

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes

Findings Presented at European Association for the Study of Diabetes (EASD) 46th Annual Meeting

PARIS, September 20, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today
results of two studies presented at the European Association for the Study of
Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled
analysis using patient-level data from randomized clinical [...]

Parents Putting Their Children at Risk due to Poor Diagnosis of Serious Illnesses

Millions of Parents are not Confident About Taking Their Child's Temperature

LONDON, September 20, 2010 – Three quarters of parents aren't confident about diagnosing illness in
their own children, according to results of a new survey released today.
Worryingly, nearly half of the parents surveyed aren't aware of the
normal body temperature range of [...]

Daxas(R) (roflumilast) Data Analysis Shows Reduction in Harmful Lung Attacks

ZURICH, September 20, 2010 -

– Global Survey Published Today Shows Long-Term Impact of Exacerbations
Seriously Underestimated[1]

– More Than Three Quarters of Patients Surveyed Suffer From
Exacerbations[1]

– New Data Analysis Released at ERS [...]

Heads of State, Leading CEOs, Entrepreneurs and World-Renowned Artists Gather in New York City From September 22-23 for the 2010 Blouin Creative Leadership Summit

NEW YORK, September 20, 2010 – The Louise Blouin Foundation (LBF) is pleased to announce the fifth
annual Blouin Creative Leadership Summit (BCLS), a forum in partnership with
the United Nations Office of Partnerships that engages in dialogue and
exchanges best practices to successfully confront the challenges and
opportunities brought about by globalization over the coming decade.

[...]

Nonin Medical to Introduce New Innovations at ERS 2010 Annual Congress

Next-Generation Wrist-Worn Pulse Oximeter, Disposable Sensors, Pulse Oximetry Clinical Guidebook, European Center Unveiled at Booth #C.100

MINNEAPOLIS, September 20, 2010 – Nonin Medical, Inc., a leading innovator of noninvasive physiological
monitoring solutions, today introduced new pulse oximetry products, a new
clinical guidebook and a new European sales, distribution and customer
service center at the European Respiratory Society (ERS) [...]

AMT’s EGM Passes All Resolutions and Strengthens Supervisory Board With Joseph Feczko, Steven Holtzman and Francois Meyer

AMSTERDAM, September 20, 2010 – Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a
leader in the field of human gene therapy, announced today that its
Extraordinary General Meeting of Shareholders passed all resolutions set out
in the Notice of the Meeting dated August 9, 2010, including an increase of
the authorized capital and the appointments of Dr. [...]

Kinetic Systems Appoints Peter M. Maris President & Chief Executive Officer

DURHAM, North Carolina, September 20, 2010 – Kinetic Systems, Inc., a leading global provider of process and
mechanical solutions to electronics, biopharmaceutical and general industry
clients, announced today the appointment of Peter M. Maris as President and
Chief Executive Officer as well as to its Board of Directors. He will also
continue to oversee the International Operations division.

[...]

Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting

Awards fund early career investigators' research to advance understanding and potential treatments of alpha1-antitrypsin deficiency

BARCELONA, Spain, September 20, 2010 – Talecris Biotherapeutics GmbH announced yesterday the recipients of the
2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The
annual awards, sponsored by Talecris, provide two fellowships of euro 50,000
to young investigators whose research aims to enhance the [...]

NewBridge Pharmaceuticals Completes US$12 Million First Close of Series B Financing, Announces Senior Executive Appointments

DUBAI, United Arab Emirates, September 20, 2010 – NewBridge Pharmaceuticals FZ-LLC of Dubai, UAE announced today that
Joseph W. Henein has been appointed President and Chief Executive Officer and
a member of the company's Board of Directors. Mr. Henein is a senior
executive who joins NewBridge after a career extending over 29 years in
multinational pharmaceutical corporations, holding [...]

Antidyslipidemics Market Forecast now Available at ReportsandReports

DALLAS, September 21, 2010 – ReportsandReports announces it will carry Antidyslipidemics Market
Forecast Research Report in its store.

Browse the complete Report on:
www.reportsandreports.com/reports/7193-antidyslipidemics-market-foreca
st.html
(Due to the length of these URLs, it may be necessary to copy and paste
the hyperlinks into your Internet browser's URL address field. Remove the
space if [...]

immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio

New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) – Study to Start in 2010

TUEBINGEN, Germany, September 21, 2010 – immatics biotechnologies GmbH, a biopharmaceutical company
developing advanced therapeutic vaccines that are active against cancer,
announced today that it has raised EUR53.8million in a Series [...]

PROMUS(R) Element(TM) Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries

NATICK, Massachusetts, September 21, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced that
its PROMUS(R) Element(TM) Everolimus-Eluting Coronary Stent System has
received CE Mark approval for use in patients with diabetes[1] and those
experiencing an acute myocardial infarction (AMI), or heart attack.

"We are pleased to receive these expanded indications for the
high-risk diabetic [...]

Wake Up and Find the Coffee With Macmillan’s Free iPhone App

…and Why Not Donate the Price of One Whilst You Sip Away!
LONDON, September 21, 2010 – The Macmillan Coffee Finder is a new free app from Macmillan Cancer
Support to help people find the best cup of coffee nearest to them. Starting
off with over 900 caf??s and coffee shops reviewed and rated around the UK,
users [...]

Almac’s Clinical Technologies Division Undergoes Successful Joint GCP-GMP MHRA Inspection

YARDLEY, Pennsylvania, September 21, 2010 – Almac's Clinical Technologies division announced today that it had
successfully passed one of the UK's first joint routine GCP/GMP Medicines and
Healthcare Products Regulatory Agency (MHRA) inspections at its Craigavon, UK
site. This involved senior MHRA inspectors from both its GCP and GMP areas
assessing compliance with UK and European legislation.

[...]

Extensi??n del programa mundial de estudios cl??nicos de la vacuna contra el dengue de Sanofi Pasteur a Brasil

Un nuevo estudio para acelerar el desarrollo de una vacuna innovadora contra el dengue, en uno de los pa??ses m??s afectados del mundo

SAO PAULO, September 21, 2010 – Sanofi Pasteur, la divisi??n vacunas del Grupo Sanofi-aventis,
anunci?? hoy el inicio de un nuevo estudio cl??nico con ni??os y adolescentes,
en Brasil, dentro del programa de desarrollo [...]

The European Social Fund Makes News

BRUSSELS, September 22, 2010 – If you're seeking a strong human interest story, then take a
look at the European Social Fund. Far from being a set of dry statistics, the
ESF is the framework for thousands of fascinating tales of individual human
endeavour.

To view the Multimedia News Release, please click:
[...]

Alberto Grua Head of Gr??nenthal Europe and Australia

MILAN, September 22, 2010 – After having handled the worldwide launch of tapentadol, the innovative
drug for the severe acute pain, Alberto Grua has been appointed Gr??nenthal
Europe and Australia Executive Vice President. Beyond the responsibility of
the Gr??nenthal subsidiaries Gr??nin both continents, Grua will be also a
member of the Group Operating Committee of Gr??nenthal Corporation.

[...]

Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus

Santaris Pharma A/S initiates Phase 2a clinical trial with miravirsen (SPC3649) to assess safety and tolerability in treatment-naive patients with chronic Hepatitis C

HOERSHOLM, Denmark and SAN DIEGO, September 22, 2010 – Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused
on the discovery and development of RNA-targeted therapies, today announced
that it has advanced miravirsen (SPC3649), the [...]

World First in Eczema Treatment

LONDON, September 22, 2010 – Following five years of research and development, Dreamskin Health Ltd is
proud to have launched the world's first range of hydrating, medical-grade
silk garments designed to relieve the itching and irritation of eczema and
dermatitis.

The secret to the new garments is a proprietary biomimetic copolymer
matrix which is firmly [...]

Elsevier Launches International Journal of Surgery Case Reports

New Journal, Included in PubMed Central, Publishes Case Reports Only and Through an Author Pays Model

OXFORD, England, September 22, 2010 – Elsevier, the world-leading publisher of scientific, technical
and medical information products and services together with Surgical
Associates Ltd the Owner of the International Journal of Surgery, announced
today the launch of the International Journal of Surgery [...]

Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium Promus Element(TM) Stent

Nine-month Results From PLATINUM Clinical Program Presented at TCT
NATICK, Massachusetts, September 22, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced data
from its PLATINUM QCA study, which is designed to evaluate the Company's
PROMUS Element(TM) Everolimus-Eluting Platinum Chromium Coronary Stent. The
results provided 30-day and nine-month clinical outcomes and nine-month
quantitative coronary angiography (QCA) and intravascular ultrasound [...]

Abbott’s Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results

Positive Data at Six and Nine Months Affirm Groundbreaking Potential of Abbott's Bioresorbable Vascular Scaffold as a Promising Alternative to Coronary Stenting

ABBOTT PARK, Illinois, September 22, 2010 – Abbott (NYSE: ABT) today announced positive nine-month results from the
first 45 patients enrolled in the second stage of the ABSORB trial. At nine
months, Abbott's bioresorbable vascular [...]

Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients

Phase II Study Published in the New England Journal of Medicine
LONDON and SAN FRANCISCO, September 22, 2010 – AstraZeneca's (LSE: AZN) new oral syk inhibitor, fostamatinib (R788),
recently in-licensed from Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL),
significantly improved outcomes of patients with rheumatoid arthritis (RA)
who responded inadequately to ongoing treatment with methotrexate (MTX),
according to phase II study [...]